Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Total Liabilities
Everything the company owes to creditors and other parties.
Apogee Therapeutics, Inc.NASDAQ: APGE
Total Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total liabilities rises 268.0% from a year ago
Total liabilities stood at $141.21M at the end of Q2 FY2026, up 268.0% from a year earlier and up 273.0% from the prior quarter. Over 3 fiscal years it compounded at +49.4% a year.
Context
- Total liabilities amounted to 10.6% of total assets at the end of Q2 FY2026, up 4.7 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +268.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 33.25M USD
- Year-over-year change
- -10.5%
- 3-year CAGR
- +49.4%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 33.25M | -10.5% |
| FY2024 | 2024-12-31 | 37.16M | +72.9% |
| FY2023 | 2023-12-31 | 21.49M | +115.3% |
| FY2022 | 2022-12-31 | 9.98M | — |
Total Liabilities vs competitors
How APGE compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +268.0% is the 2nd highest of 10, against a peer median of +25.6%.
- Total liabilities amounts to 10.6% of total assets for APGE, versus a peer median of 24.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | Dec 2025 | CN¥2.63B CNY | +12.3% | +2.8% | 66.3% |
| Mar 2026 | $1.53B USD | +31.4% | +10.4% | 117.7% | |
| Jun 2026 | $841M USD | +504.1% | +105.9% | 101.5% | |
| Jun 2026 | $467.76M USD | +25.6% | +37.8% | 43.5% | |
| Sep 2026 | $408.7M USD | -41.8% | +7.6% | 24.3% | |
| Mar 2026 | $154.42M USD | +9.1% | +14.1% | 24.1% | |
| Jun 2026 | $141.21M USD | +268.0% | +49.4% | 10.6% | |
IRONDisc Medicine, Inc. | Sep 2026 | $95.24M USD | +66.9% | +41.6% | 13.6% |
| Sep 2026 | $55.7M USD | +31.8% | +20.0% | 5.3% | |
| Sep 2026 | $53.49M USD | +10.7% | +130.5% | 4.5% | |
| Peer median (excluding APGE) | — | +25.6% | +20.0% | 24.3% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.